— Gilead has developed a new form of PrEP called Lenacapavir. Unlike many other forms of PrEP that come in pill form, Lenacapavir is an injection administered twice a year. In trials, the injection was found 100 percent effective at HIV prevention and superior to daily-administered Truvada.
— The good news is that Gilead has announced that it has signed licensing agreements with generic manufacturers to provide the injections to 120 low and middle-income countries. The bad news is that for everyone else, the price tag is $42,000 per year.
— Countries in Eastern Europe, North Africa, and Latin America are still experiencing increasing numbers of HIV infections, many of them were left out of Gilead's licensing agreement. Brazil is one such example
— Most early-stage research when clinical trials are the most likely to fail is funded by taxpayer money. The pharma industry spends $379m a year lobbying Congress to keep its R&D costs a secret.